GEN Exclusives

More »

GEN News Highlights

More »
Dec 19, 2006

PsychoGenics and Eli Lilly Form Neuropsychiatric Agreement

  • Eli Lilly will provide drug candidates that PsychoGenics will evaluate for the treatment of neuropsychiatric disorders, according to a drug discovery and development agreement.

    The agreement provides either party the option to exclusively develop any drug candidate emerging from this collaboration, with the nondeveloping party receiving milestones and royalties commensurate with the stage of development.

    PsychoGenics' technologies combine in vivo behavioral expertise together with recent developments in robotics, computer vision, and bio/cheminformatics to evaluate drug candidates for potential utility across the spectrum of neuropsychiatric disease indications.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »